Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Mol Carcinog. 2014 Feb 10;54(8):654–667. doi: 10.1002/mc.22136

Fig. 1.

Fig. 1

Dose-dependent and time-dependent effects of AMR-Me on viability and cell cycle progression of B16F10 murine melanoma cells. (A) Cytotoxicity studies as assessed by MTT assay depicting effect of various doses AMR-Me on percentage of cell viability at two different time intervals – 24 and 48 h. (B) FACS analysis showing effect of AMR-Me on B16F10 cells along with the respective graphical representation of the percentages of cells at different stages of cell cycle. (a,b) Comparison of cell cycle analysis of B16F10 cells with vehicle control and AMR-Me (10 μM) for 24 h treatment (P>0.05); (c,d) Comparison of cell cycle analysis of B16F10 cells with vehicle control and AMR-Me (5 μM) for 48 h treatment (P>0.05).